Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study.

Early reports on coronavirus disease 2019 (COVID-19) vaccines presented the short-term adverse events (AEs). This follow-up study investigated a standard regimen based on protein subunit vaccines, PastoCovac and PastoCovac Plus, and the combinational vaccine regimens including AstraZeneca/PastoCovac Plus and Sinopharm/PastoCovac Plus. The participants were followed up to 6 months post the booster shot. All the AEs were collected through in-depth interviews using a valid researcher-made questionnaire and were evaluated regarding the association with the vaccines. Of the 509 individuals, 6.2% of the combinational vaccine participants had late AEs, of whom 3.3% suffered from cutaneous manifestations, followed by 1.1% arthralgia complaints, 1.1% with neurologic disorders, 0.3% ocular problems and 0.3% metabolic complications, with no significant difference between the vaccine regimens. For the standard regimen, 2% of the individuals experienced late AEs as (1%), neurological disorders (0.3%), metabolic problems (0.3%) and involvement of joints (0.3%). Notably, 75% of the AEs were persistent up to the end of the study. A low number of late AEs were captured in 18 months as 12 improbable, 5 unclassifiable, 4 possible and 3 probable associated AEs with the vaccine regimens. The benefits of COVID-19 vaccination far exceed the potential risks and late AEs seem to be uncommon. © The Author(s) 2023. Published by Oxford University Press on behalf of FEMS.

Citation

Mona Sadat Larijani, Rahim Sorouri, Sana Eybpoosh, Delaram Doroud, Ladan Moradi, Mozhgan Ahmadinezhad, Anahita Bavand, Fatemeh Ashrafian, Parinaz Tajmehrabi Namini, Mahsan Zali, Amitis Ramezani. Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study. Pathogens and disease. 2023 Jan 17;81

Mesh Tags

Substances

PMID: 37230943

search → result